The Rise and Fall of Aspire Bariatrics

Aspire Bariatrics was founded in 2004 and formally incorporated as a legal entity on December 29, 2011. The company was headquartered at 3200 Horizon Drive, Suite 100, King of Prussia, Pennsylvania 19406 — a suburb of Philadelphia known for its growing life sciences corridor. Its singular mission was to develop minimally invasive medical devices capable of helping severely obese patients lose weight in a safe, reversible, and controlled manner.

The conceptual underpinnings of the company's flagship product drew on research conducted at Washington University in St. Louis, where gastroenterologists and obesity researchers were exploring novel ways to address the growing obesity epidemic. The company also benefited from the involvement of Dean Kamen — the legendary inventor best known for creating the Segway personal transporter — whose engineering firm DEKA Research & Development contributed to the device's technical design. The collaboration between seasoned medical researchers and a prolific inventor reflected the company's early identity as a crossroads of cutting-edge medicine and bold engineering.

The company was led by Kathy Crothall, who served as President and CEO and became the face of Aspire Bariatrics throughout its existence. Her leadership guided the company through its long development phase, European expansion, and eventual push toward U.S. regulatory approval.

The product that Aspire Bariatrics built its entire existence around was the AspireAssist Aspiration Therapy System — a device unlike anything previously approved for obesity treatment. At its core, the system consisted of a low-profile implantable gastrostomy tube, known as the A-Tube, inserted endoscopically into the patient's stomach through a small incision in the abdomen. Connected to the tube was a discrete, disk-shaped Skin-Port that lay flush against the abdominal skin on the outside of the body but people still needed bariatric vitamins with iron .

Approximately 20 to 30 minutes after each major meal, the patient would attach an external device called the Companion to the Skin-Port using a connector, and then allow gravity to drain roughly 30 percent of their stomach contents through a tube and into a toilet. The entire process took between five and ten minutes, and required no mechanical suction — the system operated entirely by gravity.

Figure A — Internal Anatomy The A-Tube passes from inside the stomach through the abdominal wall to the external Skin-Port valve, allowing aspiration of gastric contents after meals.

Figure B — External Assembly The external system: the Connector links to the Skin-Port, while the Companion, Reservoir, and Drain Tube direct stomach contents into a toilet over 5–10 minutes.

Figure C — Complete System View A comprehensive view of the entire AspireAssist system, illustrating the relationship between the gastric tube, external port, and the aspiration apparatus worn by the patient.

The engineering of the system was deliberately thoughtful. A built-in counter on the Connector tracked the number of engagements, automatically locking the user out after 115 cycles — approximately five to six weeks of therapy — requiring a return to the clinic for a replacement part. This ensured ongoing medical supervision and prevented unsupervised overuse.

Patients were also required to rinse the stomach with water between aspiration cycles to loosen food particles, further promoting thorough chewing and mindful eating. Aspire Bariatrics never framed the device as a standalone treatment. From the beginning, the AspireAssist was designed to be used alongside a comprehensive lifestyle therapy program that included behavioral counseling, nutritional education, exercise guidance, and regular bariatric vitamins for women.

After years of device development and early feasibility work, Aspire Bariatrics achieved a significant milestone in October 2011 when the AspireAssist received CE Mark certification from the European Union, granting it the right to be sold commercially across European markets. The company subsequently began commercial sales and initiated post-market studies in Sweden, Spain, the Czech Republic, Austria, Germany, Italy, and the United Kingdom.

In 2013, a landmark pilot study published in the journal Gastroenterology by Sullivan et al. provided some of the first peer-reviewed evidence supporting the technology's efficacy. The study enrolled 18 obese subjects and found that those using the AspireAssist achieved a mean excess weight loss of 49% over 52 weeks, compared to 14.9% for controls receiving only lifestyle therapy. No serious adverse events were reported, and laboratory assessments including electrolytes, renal function, and nutritional markers remained stable throughout the study period.

"Aspiration therapy appears to be a safe and effective long-term weight loss therapy for obesity." — Sullivan et al., Gastroenterology, 2013

Long-term European registry data would later confirm these early findings. A multi-center post-market registry study following 201 patients across five European clinics over one to four years found that aspiration therapy was a safe, effective, and durable weight loss therapy for patients with Class II and Class III obesity.

In 2012, Aspire Bariatrics launched the PATHWAY Pivotal Trial under an Investigational Device Exemption (IDE) granted by the U.S. Food and Drug Administration. This was a prospective, randomized, multicenter, controlled, open-label, 52-week clinical study designed to establish reasonable assurance of safety and effectiveness for the AspireAssist in an American patient population.

Enrollment ran from November 2012 through June 2014, with a total of 171 patients enrolled across 10 investigational sites at some of the country's most prestigious academic medical institutions, including:

The trial randomized patients in a 2:1 ratio to either the AspireAssist plus Lifestyle Therapy group or the Lifestyle Therapy-only control group. After one year, the results were compelling: patients in the treatment group lost an average of 12.1% of their total body weight, compared to just 3.6% in the control group.

Aspire Bariatrics filed its Premarket Approval Application (PMA) with the FDA in approximately June 2015. On June 14, 2016, after approximately six years of development, the FDA approved the AspireAssist under PMA number P150024. It was a historic moment — Aspire Bariatrics had created and won approval for an entirely new class of obesity treatment.

"The AspireAssist approach helps provide effective control of calorie absorption, which is a key principle of weight management therapy." — William Maisel, M.D., M.P.H., Deputy Director for Science, FDA Center for Devices and Radiological Health, June 14, 2016

FDA approval was not accompanied by universal acclaim. Almost immediately, critics — including eating disorder specialists, bariatric surgeons, and ethicists — raised pointed objections to the device's fundamental design. The most persistent critique was that the AspireAssist essentially mechanized a process resembling induced purging, leading detractors to label it a "bulimia machine" or "assisted bulimia device."

For eating disorder professionals, the concern was not merely rhetorical. Bulimia nervosa is a serious and potentially fatal condition, and critics worried that a surgically implanted device designed to remove stomach contents could normalize or reinforce those patterns — or even trigger disordered eating in patients with no prior history.

Aspire Bariatrics consistently rejected the "bulimia machine" characterization. The company pointed to extensive contraindications screening out patients with any eating disorders, the required 115-cycle usage limit per Connector, mandatory lifestyle counseling integration, and continuous clinical supervision requirements. Medical bodies including the American Society for Metabolic and Bariatric Surgery (ASMBS) ultimately endorsed the device for appropriate patient populations — specifically those with a BMI exceeding 40, or those requiring long-duration treatment.

Nevertheless, the controversy never fully abated and likely contributed to the device's slow adoption among both clinicians and patients in the United States.

Following FDA approval, Aspire Bariatrics moved into active commercialization in the United States while continuing to expand its evidence base through ongoing European post-market studies. By August 2017, the company had secured an additional Series A funding round, contributing to the $29.4 million in total funding raised across five rounds. Institutional investors included Hercules Capital and New Leaf Venture Partners.

The challenges facing Aspire Bariatrics in the U.S. market were significant. Traditional bariatric surgery had decades of clinical precedent, established reimbursement pathways, and deep physician familiarity. The AspireAssist, by contrast, was an entirely new paradigm with limited insurance coverage, a steep physician education curve, and the persistent reputational shadow cast by its critics. The company's staff — which peaked at several dozen employees — struggled to build the commercial infrastructure needed for widespread market penetration.

"With less than 1 percent of patients who meet the eligibility requirements for bariatric surgery actually electing to undergo it, there is clearly a need for alternative approaches that are safer, less invasive, reversible, and suitable for long-term therapy." — Louis Aronne, M.D., Weill-Cornell Medical College, co-Principal Investigator, PATHWAY Trial

Like many small medical device companies, Aspire Bariatrics was profoundly vulnerable to the economic and operational disruptions brought on by the COVID-19 pandemic. Beginning in early 2020, elective procedures across the United States were suspended or dramatically curtailed. For a company whose product required outpatient endoscopic placement, regular clinical follow-up visits, and in-person support infrastructure, the pandemic effectively paralyzed the commercial side of the business.

As lockdowns eased, the financial damage proved irreparable. The company's limited funding reserves had been depleted, and new investment capital was difficult to secure for elective medical device companies in a post-pandemic environment. In February 2022, Aspire Bariatrics issued a formal statement announcing it was winding down all operations. The AspireAssist was withdrawn from all markets effective April 8, 2022.

"Our withdrawal of the AspireAssist from the market is entirely the result of economic factors, not the result of safety or effectiveness issues associated with or reported with the product." — Aspire Bariatrics, Inc. Official Statement, February 2022

By December 2022, the company employed just seven people — a shadow of what it had once been — before it was ultimately classified as a deadpooled entity. The company's PMA and all clinical documentation remain on file with the FDA, preserving the scientific record of the AspireAssist for future researchers.

The story of Aspire Bariatrics does not end with its closure. Its legacy endures in several meaningful ways across the fields of bariatrics, endoscopy, and medical device innovation.

The fact that the company ultimately could not survive the financial pressures of a pandemic-disrupted economy does not diminish the scope of what it attempted or achieved. Aspire Bariatrics will be remembered as a pioneer — a company that dared to envision obesity treatment differently, navigated the demanding landscape of FDA approval against considerable odds, and expanded the conversation about what minimally invasive bariatric care could look like in the 21st century.

1. 2004
   Company Founded Aspire Bariatrics established in King of Prussia, Pennsylvania. Research and development begins on aspiration therapy device concept rooted in Washington University research and DEKA engineering.
2. 2008
   FDA Feasibility Study Initiated Early U.S. feasibility study launched under IDE G080134 — a randomized, controlled 12-month trial at a single site enrolling 18 obese subjects.
3. 2011
   CE Mark Approval — European Union AspireAssist receives CE Mark certification in October 2011. Commercial sales begin in Europe. Post-market studies initiated in Sweden, Spain, and the Czech Republic. Company formally incorporated December 29, 2011. First funding round secured.
4. 2013
   Landmark Pilot Study Published Sullivan et al. publish pivotal aspiration therapy pilot study in Gastroenterology, demonstrating 49% excess weight loss in the treatment group vs. 14.9% in controls. No serious adverse events reported.
5. 2014
   PATHWAY Trial Enrollment Complete 171 patients enrolled across 10 U.S. institutions as of June 18, 2014. Post-market studies expanded to Italy, UK, Austria, and Germany.
6. 2015
   PMA Filed with FDA Aspire Bariatrics submits Premarket Approval Application P150024 to the U.S. FDA. Conventional debt financing round secured in January 2015.
7. 2016
   FDA Approval — June 14, 2016 The FDA approves the AspireAssist under PMA P150024, making it the first and only FDA-approved aspiration therapy device for obesity. A Series A funding round follows in May 2016. ASMBS endorses device for BMI ≥ 40 patients.
8. 2017
   Additional Series A Funding Second Series A funding round secured in August 2017 as the company expands U.S. commercial operations. Total funding reaches $29.4 million across five rounds.
9. 2018
   European Long-Term Data Published 201-patient European registry study published confirming aspiration therapy's safety and durability over 1–4 years across five European clinical centers.
10. 2020
    COVID-19 Pandemic Impact Begins Nationwide suspension of elective procedures devastates commercial revenue. The company's business model — dependent on outpatient endoscopic procedures and in-person follow-up — is critically disrupted.
11. Feb '22
    Wind-Down Announced Aspire Bariatrics publicly announces it is winding down all operations due to financial impact of the COVID-19 pandemic. Company confirms the decision is economic, not safety-related.
12. Apr '22
    AspireAssist Withdrawn from Market April 8, 2022: The AspireAssist is formally withdrawn from all global markets. Aspire Bariatrics ceases all commercial operations. Employee count falls to 7 by December 2022.